Press Release: Zealand Pharma convenes its Annual General Meeting 2026

Dow Jones
02/19

Company announcement -- No. 2 / 2026

Zealand Pharma convenes its Annual General Meeting 2026

Copenhagen, Denmark, February 19, 2026 -- Zealand Pharma A/S ("the Company" or "Zealand Pharma") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby convenes its Annual General Meeting 2026.

The Board of Directors of Zealand Pharma A/S hereby convenes the Annual General Meeting of the Company to be held on:

Thursday, 26 March 2026 at 03:00 PM $(CET)$ / 9:00 $(ET)$

The Annual General Meeting will be held as a partly electronic general meeting (hybrid meeting), allowing shareholders to participate either electronically or in person.

The meeting will be conducted electronically via the virtual meeting portal hosted by Computershare A/S, and physically at the Company's registered office at Sydmarken 11, DK--2860 Søborg, Denmark.

Further information, including the agenda and practical details regarding participation and voting, is set out in the accompanying materials.

# # #

About Zealand Pharma

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data--driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than ten Zealand Pharma--invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.

Contacts

Adam Lange (Investors)

Vice President, Investor Relations

Zealand Pharma

Email: alange@zealandpharma.com

Neshat Ahmadi (Investors)

Investor Relations Manager

Zealand Pharma

Email: neahmadi@zealandpharma.com

Rachel James-Owens (Media)

Vice President, Corporate Communications & Media Relations

Zealand Pharma

RJamesOwens@zealandpharma.com

Attachment

   -- Zealand Pharma - AGM 2026 Notice 

(END) Dow Jones Newswires

February 19, 2026 08:00 ET (13:00 GMT)

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10